Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862688 | 0.89 | SMN1; SMN2 (0.53) | ALDH1A1RAB9AKDM4EMAPTL3MBTL1 | |
| SCHEMBL5861519 | 0.86 | TRPM8 (0.47) | ALDH1A1RAB9AKDM4EMAPTL3MBTL1 | |
| SCHEMBL5860443 | 0.84 | L3MBTL1 (0.41) | ALDH1A1RAB9AKDM4EL3MBTL1NPC1 | |
| SCHEMBL5861527 | 0.83 | RAB9A (0.46) | ALDH1A1RAB9AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL7787285 | 0.80 | TRPM8 (0.45) | ALDH1A1RAB9AKDM4EMAPTL3MBTL1 | |
| SCHEMBL5860161 | 0.80 | POLB (0.49) | ALDH1A1RAB9AMAPTL3MBTL1NPC1 | |
| SCHEMBL7780059 | 0.78 | RAB9A (0.43) | ALDH1A1RAB9AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL5861486 | 0.76 | ALDH1A1 (0.65) | ATMALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL5140898 | 0.75 | CYP1A2 (0.48) | ALDH1A1RAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL5862781 | 0.75 | ALDH1A1 (0.47) | ALDH1A1RAB9AKDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| US-20020169203-A1 | Ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-11-14 | — | — | US | claimed |
| EP-1140784-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-10 | — | — | EP | claimed |
| WO-2000037422-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-29 | — | — | WO | claimed |
| US-7012146-B2 | Ion channel modulating agents | POSEIDON PHARMACEUTICALS A/S (DK) | 2006-03-14 | — | — | US | disclosed |
| EP-1345618-B1 | CHLORZOXAZONE FOR THE TREATMENT OF PSORIASIS | SWITCH BIOTECH AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| US-20040248099-A1 | Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | disclosed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| EP-1345618-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | Switch Biotech Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020169203-A1 | Ion channel modulating agents | NEUROSEARCH A/S (DK) | 2002-11-14 | — | — | US | disclosed |
| WO-2002053171-A2 | USE OF INTERMEDIATE-CONDUCTANCE POTASSIUM CHANNELS AND MODULATORS FOR THE DIAGNOSIS AND TREATMENT OF ILLNESSES HAVING DISTURBED KERATINOCYTE ACTIVITY | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | WO | disclosed |
| EP-1140784-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037422-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169203-A1 | Ion channel modulating agents | KCNN3, KCNN1, KCNN2 | ATM 4116/4885ALDH1A1 4482/4885RAB9A 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.